Michael O'Riordan is a Senior Journalist for TCTMD, specializing in the field of cardiology and cardiovascular research. With a focus on providing up-to-date and accurate information, Michael's articles cover a wide range of topics including clinical trials, treatment options, and emerging trends in the field of cardiology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael O'Riordan's articles predominantly cite data and cover topics related to cardiovascular disease, medical research, treatment options, and risk factors. He would likely be receptive to pitches offering insights from experts in the healthcare and pharmaceutical industry who can provide informed perspectives on new research findings, treatment developments, or changes in medical guidelines related to cardiovascular diseases.
Given his focus on citing data extensively in his coverage, he may appreciate pitches that offer access to proprietary or exclusive datasets relevant to the topics he covers. Additionally, sources with a deep understanding of scientific methodologies and clinical trial design could capture Michael's interest.
While there is no specified geographic focus for Michael's work, his articles appear internationally focused based on the subjects covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
It was initially thought Lp(a) would need to be measured only once, but data suggest it can fluctuate in some people.
Body mass index still has uses as a gateway to broader investigations into obesity, says a BRI co-developer.
Evolut Pro/Pro+ valves had the lowest rate of cannulation, but next-gen devices are poised to overcome access challenges.
In this underpowered trial, using CMR to guide AVR timing did not nudge the primary endpoint, but did trim AS hospitalizations.
By: Michael O'Riordan
New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.
The study conflicts with two prior trials showing a benefit and may warrant colchicine's reconsideration in the guidelines.
By: Michael O Riordan
The benefit was confined to symptoms, but in a very sick population with few options, that's important, say researchers.
The trial was small and halted early, but investigators say the inflammatory hypothesis in TAVI is worth pursuing further.
Just 15% of patients have their filters taken out despite clear recommendations they should be removed as soon as feasible.
While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.
(833) 317-6278 
